Literature DB >> 8062282

Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo.

J P Witty1, S McDonnell, K J Newell, P Cannon, M Navre, R J Tressler, L M Matrisian.   

Abstract

The expression of the metalloproteinase matrilysin in the human colon carcinoma cell lines SW480 and SW620 correlates with the ability of the SW620 cells to invade an artificial basement membrane in vitro and metastasize to the liver following injection into the cecum of nude mice in vivo. Transfection of either wild-type or activated forms of matrilysin into the SW480 cells, which do not express endogenous matrilysin, did not reproducibly increase in vitro invasion but increased the tumorigenicity of the cells when injected into the cecum of nude mice. Antisense reduction of matrilysin levels decreased the tumorigenicity of the SW620 cells and subsequent metastasis to the liver. These results suggest that matrilysin gene expression by colon adenocarcinoma cells is not sufficient for tumor invasion and metastasis but contributes to the tumorigenicity and progression of colorectal tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8062282

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression.

Authors:  Steven T Sizemore; Ruth A Keri
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

3.  Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.

Authors:  Zhongsheng Peng; Jiayan Chen; Cinthia B Drachenberg; Jean-Pierre Raufman; Guofeng Xie
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

4.  Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression.

Authors:  D L Crowe; K J Tsang; B Shemirani
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

5.  Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems.

Authors:  M Cecilia Subauste; Tatyana A Kupriyanova; Erin M Conn; Veronica C Ardi; James P Quigley; Elena I Deryugina
Journal:  Clin Exp Metastasis       Date:  2009-10-20       Impact factor: 5.150

6.  Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin.

Authors:  C L Wilson; K J Heppner; P A Labosky; B L Hogan; L M Matrisian
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

7.  The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors.

Authors:  H C Crawford; B Fingleton; M D Gustavson; N Kurpios; R A Wagenaar; J A Hassell; L M Matrisian
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

8.  Helicobacter pylori upregulates matrilysin (MMP-7) in epithelial cells in vivo and in vitro in a Cag dependent manner.

Authors:  J R Bebb; D P Letley; R J Thomas; F Aviles; H M Collins; S A Watson; N M Hand; A Zaitoun; J C Atherton
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

9.  Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity.

Authors:  J Oliver McIntyre; Barbara Fingleton; K Sam Wells; David W Piston; Conor C Lynch; Shiva Gautam; Lynn M Matrisian
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

10.  The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.

Authors:  Vanessa Almendro; Elisabet Ametller; Susana García-Recio; Olga Collazo; Ignasi Casas; Josep M Augé; Joan Maurel; Pedro Gascón
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.